Suppr超能文献

氯沙坦用于心力衰竭:临床前研究经验及初步临床结果。

Losartan in heart failure: preclinical experiences and initial clinical outcomes.

作者信息

Sweet C S, Rucinska E J

机构信息

Merck Research Laboratories, Clinical Cardiovascular Research, West Point, PA 19486.

出版信息

Eur Heart J. 1994 Dec;15 Suppl D:139-44. doi: 10.1093/eurheartj/15.suppl_d.139.

Abstract

Losartan potassium (Cozaar) is an angiotensin II receptor antagonist (AT1 selective) which has undergone extensive clinical trials for the treatment of hypertension. This literature survey will review some of the pre-clinical findings with losartan in models of heart failure, and where appropriate, we will compare the haemodynamic findings in animals with similar studies completed in patients. The major conclusion from these trials is that losartan has clear haemodynamic benefits in patients in heart failure and that the drug appears to be well tolerated, with a low incidence of adverse experiences related to impaired renal function.

摘要

氯沙坦钾(科素亚)是一种血管紧张素II受体拮抗剂(AT1选择性),已针对高血压治疗进行了广泛的临床试验。本文献综述将回顾氯沙坦在心力衰竭模型中的一些临床前研究结果,并在适当情况下,将动物的血流动力学研究结果与在患者中完成的类似研究进行比较。这些试验的主要结论是,氯沙坦对心力衰竭患者有明显的血流动力学益处,且该药物似乎耐受性良好,与肾功能受损相关的不良事件发生率较低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验